Portfolio Holdings Detail for ISIN IE00BFF5RZ82
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Edge MSCI USA Momentum Factor UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker IUMD(USD) LSE
ETF Ticker IUMD.L(GBP) LSE

Holdings detail for ALNY

Stock Name	Alnylam Pharmaceuticals Inc
Ticker	ALNY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US02043Q1076
LEI	529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win: Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer: Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial: Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares Edge MSCI USA Momentum Factor UCITS ETF USD (Dist) ALNY holdings

Date	Number of ALNY Shares Held	Base Market Value of ALNY Shares	Local Market Value of ALNY Shares	Change in ALNY Shares Held	Change in ALNY Base Value	Current Price per ALNY Share Held	Previous Price per ALNY Share Held
2025-11-11 (Tuesday)	6,774	USD 3,061,509	USD 3,061,509	0	USD 69,433	USD 451.95	USD 441.7
2025-11-10 (Monday)	6,774	USD 2,992,076	USD 2,992,076	-172	USD -82,918	USD 441.7	USD 442.7
2025-11-07 (Friday)	6,946	USD 3,074,994	USD 3,074,994	0	USD 15,350	USD 442.7	USD 440.49
2025-11-06 (Thursday)	6,946	USD 3,059,644	USD 3,059,644	-86	USD 3,818	USD 440.49	USD 434.56
2025-11-05 (Wednesday)	7,032	USD 3,055,826	USD 3,055,826	0	USD 77,985	USD 434.56	USD 423.47
2025-11-04 (Tuesday)	7,032	USD 2,977,841	USD 2,977,841	0	USD -74,539	USD 423.47	USD 434.07
2025-11-03 (Monday)	7,032	USD 3,052,380	USD 3,052,380	172	USD -76,054	USD 434.07	USD 456.04
2025-10-31 (Friday)	6,860	USD 3,128,434	USD 3,128,434	0	USD 44,452	USD 456.04	USD 449.56
2025-10-30 (Thursday)	6,860	USD 3,083,982	USD 3,083,982	0	USD -219,725	USD 449.56	USD 481.59
2025-10-29 (Wednesday)	6,860	USD 3,303,707	USD 3,303,707	0	USD 38,964	USD 481.59	USD 475.91
2025-10-28 (Tuesday)	6,860	USD 3,264,743	USD 3,264,743	0	USD -18,316	USD 475.91	USD 478.58
2025-10-27 (Monday)	6,860	USD 3,283,059	USD 3,283,059	0	USD 103,929	USD 478.58	USD 463.43

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BFF5RZ82

Show aggregate share trades of ALNY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 SELL -172 449.680 440.930 441.805 USD -75,990 307.44 Loss of -23,110 on sale
2025-11-06 SELL -86 445.490 429.000 430.649 USD -37,036 306.21 Loss of -10,701 on sale
2025-11-03 BUY 172 457.260 429.615 432.379 USD 74,369 304.48
2025-10-24 SELL -86 463.430 469.290 468.704 USD -40,309 299.80 Loss of -14,526 on sale
2025-10-23 BUY 172 464.000 468.860 468.374 USD 80,560 299.01
2025-10-22 BUY 86 464.900 480.530 478.967 USD 41,191 298.21
2025-10-21 SELL -85 474.000 490.050 488.445 USD -41,518 297.35 Loss of -16,243 on sale
2025-10-20 BUY 85 491.220 495.550 495.117 USD 42,085 296.41
2025-10-14 SELL -86 469.360 479.690 478.657 USD -41,165 292.84 Loss of -15,980 on sale
2025-10-13 BUY 258 464.950 473.650 472.780 USD 121,977 291.98
2025-10-01 BUY 255 460.650 467.420 466.743 USD 119,019 288.60
2025-09-30 BUY 85 456.000 459.300 458.970 USD 39,012 287.74
2025-09-12 BUY 85 465.890 475.690 474.710 USD 40,350 280.63
2025-09-11 SELL -85 468.580 474.340 473.764 USD -40,270 279.62 Loss of -16,503 on sale
2025-07-31 BUY 64 392.240 402.430 401.411 USD 25,690 274.94
2025-07-30 SELL -64 339.800 345.980 345.362 USD -22,103 274.58 Loss of -4,530 on sale
2025-07-25 SELL -64 328.810 331.500 331.231 USD -21,199 273.67 Loss of -3,684 on sale
2025-07-24 BUY 128 328.000 332.190 331.771 USD 42,467 273.36
2025-07-14 SELL -64 315.750 319.180 318.837 USD -20,406 272.00 Loss of -2,998 on sale
2025-07-11 SELL -256 314.940 321.120 320.502 USD -82,049 271.75 Loss of -12,481 on sale
2025-07-10 BUY 384 322.640 324.820 324.602 USD 124,647 271.45
2025-07-07 SELL -252 324.130 328.240 327.829 USD -82,613 270.55 Loss of -14,433 on sale
2025-07-03 SELL -63 331.910 333.700 333.521 USD -21,012 269.81 Loss of -4,014 on sale
2025-06-30 SELL -252 326.090 327.210 327.098 USD -82,429 269.09 Loss of -14,619 on sale
2025-06-27 BUY 504 322.830 323.200 323.163 USD 162,874 268.75
2025-06-24 SELL -189 325.000 326.030 325.927 USD -61,600 267.75 Loss of -10,996 on sale
2025-06-23 SELL -63 313.130 314.780 314.615 USD -19,821 267.46 Loss of -2,971 on sale
2025-06-20 SELL -189 309.700 314.500 314.020 USD -59,350 267.19 Loss of -8,851 on sale
2025-06-18 SELL -248 312.320 317.540 317.018 USD -78,620 266.60 Loss of -12,503 on sale
2025-06-17 BUY 372 308.710 309.060 309.025 USD 114,957 266.33
2025-06-13 BUY 124 307.990 308.020 308.017 USD 38,194 265.77
2025-06-12 SELL -620 304.670 307.480 307.199 USD -190,463 265.51 Loss of -25,847 on sale
2025-06-11 BUY 124 298.580 303.850 303.323 USD 37,612 265.29
2025-06-05 SELL -62 308.000 308.530 308.477 USD -19,126 264.23 Loss of -2,744 on sale
2025-06-04 BUY 62 305.310 308.930 308.568 USD 19,131 263.94
2025-05-30 SELL -1,740 304.560 306.000 305.856 USD -532,189 263.07 Loss of -74,446 on sale
2025-05-29 SELL -88 292.900 293.220 293.188 USD -25,801 262.86 Loss of -2,669 on sale
2025-05-23 SELL -176 289.960 291.220 291.094 USD -51,233 262.09 Loss of -5,104 on sale
2025-05-22 SELL -176 289.000 291.540 291.286 USD -51,266 261.89 Loss of -5,173 on sale
2025-05-20 BUY 88 291.680 292.990 292.859 USD 25,772 261.44
2025-05-19 BUY 176 291.860 296.800 296.306 USD 52,150 261.21
2025-05-16 BUY 264 285.310 289.750 289.306 USD 76,377 261.02
2025-05-15 BUY 88 283.400 285.000 284.840 USD 25,066 260.85
2025-05-12 BUY 352 270.190 270.200 270.199 USD 95,110 260.68
2025-05-07 BUY 88 276.550 277.850 277.720 USD 24,439 260.65
2025-04-25 SELL -87 251.560 253.250 253.081 USD -22,018 260.65 Profit of 658 on sale
2025-04-23 BUY 87 241.970 248.590 247.928 USD 21,570 260.97
2025-04-22 BUY 87 236.750 238.630 238.442 USD 20,744 261.19
2025-04-15 SELL -261 230.930 242.150 241.028 USD -62,908 262.51 Profit of 5,606 on sale
2025-04-10 SELL -261 226.280 235.330 234.425 USD -61,185 263.30 Profit of 7,537 on sale
2025-04-07 SELL -87 232.950 241.830 240.942 USD -20,962 264.18 Profit of 2,021 on sale
2025-04-02 SELL -87 266.830 267.290 267.244 USD -23,250 264.44 Loss of -244 on sale
2025-04-01 BUY 87 255.760 273.610 271.825 USD 23,649 264.52
2025-03-31 SELL -174 270.020 271.850 271.667 USD -47,270 264.47 Loss of -1,253 on sale
2025-03-28 SELL -87 268.460 271.300 271.016 USD -23,578 264.43 Loss of -573 on sale
2025-03-25 SELL -88 280.960 292.620 291.454 USD -25,648 264.13 Loss of -2,405 on sale
2025-03-21 BUY 174 283.340 289.440 288.830 USD 50,256 263.63
2025-03-19 BUY 87 253.440 255.350 255.159 USD 22,199 263.86
2025-03-18 SELL -87 244.300 263.300 261.400 USD -22,742 264.08 Profit of 233 on sale
2025-03-17 BUY 174 253.110 253.300 253.281 USD 44,071 264.20
2025-03-13 SELL -87 241.750 245.140 244.801 USD -21,298 264.72 Profit of 1,733 on sale
2025-03-07 BUY 87 244.520 251.120 250.460 USD 21,790 265.94
2025-03-05 BUY 261 249.230 249.820 249.761 USD 65,188 266.15
2025-02-26 BUY 95 243.860 251.600 250.826 USD 23,828 267.68
2025-02-25 SELL -87 245.200 251.560 250.924 USD -21,830 267.98 Profit of 1,484 on sale
2025-02-21 SELL -87 250.590 253.700 253.389 USD -22,045 268.48 Profit of 1,313 on sale
2025-02-12 BUY 88 265.960 268.200 267.976 USD 23,582 269.76
2025-02-06 BUY 88 278.250 279.240 279.141 USD 24,564 269.46
2025-01-31 SELL -88 271.310 279.340 278.537 USD -24,511 269.20 Loss of -822 on sale
2025-01-29 SELL -88 273.990 279.700 279.129 USD -24,563 268.97 Loss of -894 on sale
2025-01-28 SELL -176 279.190 283.560 283.123 USD -49,830 268.78 Loss of -2,524 on sale
2025-01-24 BUY 264 278.760 279.670 279.579 USD 73,809 268.44
2025-01-23 SELL -176 275.540 277.220 277.052 USD -48,761 268.31 Loss of -1,539 on sale
2025-01-02 SELL -88 233.620 239.990 239.353 USD -21,063 268.99 Profit of 2,608 on sale
2024-12-09 SELL -88 255.890 258.120 257.897 USD -22,695 269.56 Profit of 1,027 on sale
2024-12-06 BUY 174 256.260 257.810 257.655 USD 44,832 269.84
2024-11-25 SELL -1,127 250.980 255.460 255.012 USD -287,399 274.91 Profit of 22,427 on sale
2024-11-25 SELL -1,127 250.980 255.460 255.012 USD -287,399 274.91 Profit of 22,427 on sale
2024-11-22 BUY 103 244.890 248.900 248.499 USD 25,595 275.75
2024-11-20 BUY 103 248.790 249.100 249.069 USD 25,654 277.39
2024-11-18 BUY 206 232.270 242.490 241.468 USD 49,742 280.15
2024-11-12 BUY 408 268.950 270.770 270.588 USD 110,400 280.89
2024-11-12 BUY 408 268.950 270.770 270.588 USD 110,400 280.89
2024-11-07 BUY 102 272.220 275.070 274.785 USD 28,028 281.83
2024-11-07 BUY 102 272.220 275.070 274.785 USD 28,028 281.83
2024-11-04 SELL -309 269.950 272.920 272.623 USD -84,241 285.55 Profit of 3,994 on sale
2024-11-04 SELL -309 269.950 272.920 272.623 USD -84,241 285.55 Profit of 3,994 on sale
2024-10-30 BUY 103 281.490 287.870 287.232 USD 29,585 290.50
2024-10-30 BUY 103 281.490 287.870 287.232 USD 29,585 290.50
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	SELL	-172	449.680	440.930	441.805	USD -75,990	307.44 Loss of -23,110 on sale
2025-11-06	SELL	-86	445.490	429.000	430.649	USD -37,036	306.21 Loss of -10,701 on sale
2025-11-03	BUY	172	457.260	429.615	432.379	USD 74,369	304.48
2025-10-24	SELL	-86	463.430	469.290	468.704	USD -40,309	299.80 Loss of -14,526 on sale
2025-10-23	BUY	172	464.000	468.860	468.374	USD 80,560	299.01
2025-10-22	BUY	86	464.900	480.530	478.967	USD 41,191	298.21
2025-10-21	SELL	-85	474.000	490.050	488.445	USD -41,518	297.35 Loss of -16,243 on sale
2025-10-20	BUY	85	491.220	495.550	495.117	USD 42,085	296.41
2025-10-14	SELL	-86	469.360	479.690	478.657	USD -41,165	292.84 Loss of -15,980 on sale
2025-10-13	BUY	258	464.950	473.650	472.780	USD 121,977	291.98
2025-10-01	BUY	255	460.650	467.420	466.743	USD 119,019	288.60
2025-09-30	BUY	85	456.000	459.300	458.970	USD 39,012	287.74
2025-09-12	BUY	85	465.890	475.690	474.710	USD 40,350	280.63
2025-09-11	SELL	-85	468.580	474.340	473.764	USD -40,270	279.62 Loss of -16,503 on sale
2025-07-31	BUY	64	392.240	402.430	401.411	USD 25,690	274.94
2025-07-30	SELL	-64	339.800	345.980	345.362	USD -22,103	274.58 Loss of -4,530 on sale
2025-07-25	SELL	-64	328.810	331.500	331.231	USD -21,199	273.67 Loss of -3,684 on sale
2025-07-24	BUY	128	328.000	332.190	331.771	USD 42,467	273.36
2025-07-14	SELL	-64	315.750	319.180	318.837	USD -20,406	272.00 Loss of -2,998 on sale
2025-07-11	SELL	-256	314.940	321.120	320.502	USD -82,049	271.75 Loss of -12,481 on sale
2025-07-10	BUY	384	322.640	324.820	324.602	USD 124,647	271.45
2025-07-07	SELL	-252	324.130	328.240	327.829	USD -82,613	270.55 Loss of -14,433 on sale
2025-07-03	SELL	-63	331.910	333.700	333.521	USD -21,012	269.81 Loss of -4,014 on sale
2025-06-30	SELL	-252	326.090	327.210	327.098	USD -82,429	269.09 Loss of -14,619 on sale
2025-06-27	BUY	504	322.830	323.200	323.163	USD 162,874	268.75
2025-06-24	SELL	-189	325.000	326.030	325.927	USD -61,600	267.75 Loss of -10,996 on sale
2025-06-23	SELL	-63	313.130	314.780	314.615	USD -19,821	267.46 Loss of -2,971 on sale
2025-06-20	SELL	-189	309.700	314.500	314.020	USD -59,350	267.19 Loss of -8,851 on sale
2025-06-18	SELL	-248	312.320	317.540	317.018	USD -78,620	266.60 Loss of -12,503 on sale
2025-06-17	BUY	372	308.710	309.060	309.025	USD 114,957	266.33
2025-06-13	BUY	124	307.990	308.020	308.017	USD 38,194	265.77
2025-06-12	SELL	-620	304.670	307.480	307.199	USD -190,463	265.51 Loss of -25,847 on sale
2025-06-11	BUY	124	298.580	303.850	303.323	USD 37,612	265.29
2025-06-05	SELL	-62	308.000	308.530	308.477	USD -19,126	264.23 Loss of -2,744 on sale
2025-06-04	BUY	62	305.310	308.930	308.568	USD 19,131	263.94
2025-05-30	SELL	-1,740	304.560	306.000	305.856	USD -532,189	263.07 Loss of -74,446 on sale
2025-05-29	SELL	-88	292.900	293.220	293.188	USD -25,801	262.86 Loss of -2,669 on sale
2025-05-23	SELL	-176	289.960	291.220	291.094	USD -51,233	262.09 Loss of -5,104 on sale
2025-05-22	SELL	-176	289.000	291.540	291.286	USD -51,266	261.89 Loss of -5,173 on sale
2025-05-20	BUY	88	291.680	292.990	292.859	USD 25,772	261.44
2025-05-19	BUY	176	291.860	296.800	296.306	USD 52,150	261.21
2025-05-16	BUY	264	285.310	289.750	289.306	USD 76,377	261.02
2025-05-15	BUY	88	283.400	285.000	284.840	USD 25,066	260.85
2025-05-12	BUY	352	270.190	270.200	270.199	USD 95,110	260.68
2025-05-07	BUY	88	276.550	277.850	277.720	USD 24,439	260.65
2025-04-25	SELL	-87	251.560	253.250	253.081	USD -22,018	260.65 Profit of 658 on sale
2025-04-23	BUY	87	241.970	248.590	247.928	USD 21,570	260.97
2025-04-22	BUY	87	236.750	238.630	238.442	USD 20,744	261.19
2025-04-15	SELL	-261	230.930	242.150	241.028	USD -62,908	262.51 Profit of 5,606 on sale
2025-04-10	SELL	-261	226.280	235.330	234.425	USD -61,185	263.30 Profit of 7,537 on sale
2025-04-07	SELL	-87	232.950	241.830	240.942	USD -20,962	264.18 Profit of 2,021 on sale
2025-04-02	SELL	-87	266.830	267.290	267.244	USD -23,250	264.44 Loss of -244 on sale
2025-04-01	BUY	87	255.760	273.610	271.825	USD 23,649	264.52
2025-03-31	SELL	-174	270.020	271.850	271.667	USD -47,270	264.47 Loss of -1,253 on sale
2025-03-28	SELL	-87	268.460	271.300	271.016	USD -23,578	264.43 Loss of -573 on sale
2025-03-25	SELL	-88	280.960	292.620	291.454	USD -25,648	264.13 Loss of -2,405 on sale
2025-03-21	BUY	174	283.340	289.440	288.830	USD 50,256	263.63
2025-03-19	BUY	87	253.440	255.350	255.159	USD 22,199	263.86
2025-03-18	SELL	-87	244.300	263.300	261.400	USD -22,742	264.08 Profit of 233 on sale
2025-03-17	BUY	174	253.110	253.300	253.281	USD 44,071	264.20
2025-03-13	SELL	-87	241.750	245.140	244.801	USD -21,298	264.72 Profit of 1,733 on sale
2025-03-07	BUY	87	244.520	251.120	250.460	USD 21,790	265.94
2025-03-05	BUY	261	249.230	249.820	249.761	USD 65,188	266.15
2025-02-26	BUY	95	243.860	251.600	250.826	USD 23,828	267.68
2025-02-25	SELL	-87	245.200	251.560	250.924	USD -21,830	267.98 Profit of 1,484 on sale
2025-02-21	SELL	-87	250.590	253.700	253.389	USD -22,045	268.48 Profit of 1,313 on sale
2025-02-12	BUY	88	265.960	268.200	267.976	USD 23,582	269.76
2025-02-06	BUY	88	278.250	279.240	279.141	USD 24,564	269.46
2025-01-31	SELL	-88	271.310	279.340	278.537	USD -24,511	269.20 Loss of -822 on sale
2025-01-29	SELL	-88	273.990	279.700	279.129	USD -24,563	268.97 Loss of -894 on sale
2025-01-28	SELL	-176	279.190	283.560	283.123	USD -49,830	268.78 Loss of -2,524 on sale
2025-01-24	BUY	264	278.760	279.670	279.579	USD 73,809	268.44
2025-01-23	SELL	-176	275.540	277.220	277.052	USD -48,761	268.31 Loss of -1,539 on sale
2025-01-02	SELL	-88	233.620	239.990	239.353	USD -21,063	268.99 Profit of 2,608 on sale
2024-12-09	SELL	-88	255.890	258.120	257.897	USD -22,695	269.56 Profit of 1,027 on sale
2024-12-06	BUY	174	256.260	257.810	257.655	USD 44,832	269.84
2024-11-25	SELL	-1,127	250.980	255.460	255.012	USD -287,399	274.91 Profit of 22,427 on sale
2024-11-25	SELL	-1,127	250.980	255.460	255.012	USD -287,399	274.91 Profit of 22,427 on sale
2024-11-22	BUY	103	244.890	248.900	248.499	USD 25,595	275.75
2024-11-20	BUY	103	248.790	249.100	249.069	USD 25,654	277.39
2024-11-18	BUY	206	232.270	242.490	241.468	USD 49,742	280.15
2024-11-12	BUY	408	268.950	270.770	270.588	USD 110,400	280.89
2024-11-12	BUY	408	268.950	270.770	270.588	USD 110,400	280.89
2024-11-07	BUY	102	272.220	275.070	274.785	USD 28,028	281.83
2024-11-07	BUY	102	272.220	275.070	274.785	USD 28,028	281.83
2024-11-04	SELL	-309	269.950	272.920	272.623	USD -84,241	285.55 Profit of 3,994 on sale
2024-11-04	SELL	-309	269.950	272.920	272.623	USD -84,241	285.55 Profit of 3,994 on sale
2024-10-30	BUY	103	281.490	287.870	287.232	USD 29,585	290.50
2024-10-30	BUY	103	281.490	287.870	287.232	USD 29,585	290.50

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	216,727	3,259	396,243	54.7%
2025-09-18	172,875	397	386,432	44.7%
2025-09-17	246,547	167	472,292	52.2%
2025-09-16	88,846	60	226,336	39.3%
2025-09-15	148,258	13,572	435,689	34.0%
2025-09-12	134,122	300	244,968	54.8%
2025-09-11	219,868	7,820	411,702	53.4%
2025-09-10	543,326	7,595	916,898	59.3%
2025-09-09	705,540	33,731	1,550,899	45.5%
2025-09-08	175,158	440	388,715	45.1%
2025-09-05	127,116	335	311,252	40.8%
2025-09-04	110,930	2,555	236,568	46.9%
2025-09-03	182,386	8,982	562,921	32.4%
2025-09-02	132,770	14,416	358,476	37.0%
2025-08-29	93,216	2,181	276,594	33.7%
2025-08-28	60,182	1,254	226,865	26.5%
2025-08-27	277,667	1,084	440,577	63.0%
2025-08-26	243,404	919	447,421	54.4%
2025-08-25	156,551	15,662	374,276	41.8%
2025-08-22	228,596	1,309	408,152	56.0%
2025-08-21	123,996	2,862	248,300	49.9%
2025-08-20	149,638	13,723	316,983	47.2%
2025-08-19	144,320	1,143	308,399	46.8%
2025-08-18	371,318	34,264	525,786	70.6%
2025-08-15	104,018	13,245	265,620	39.2%
2025-08-14	133,272	4,443	505,528	26.4%
2025-08-13	183,271	1,390	1,017,623	18.0%
2025-08-12	173,045	4,046	693,018	25.0%
2025-08-11	239,199	7,600	451,248	53.0%
2025-08-08	168,755	3,199	466,744	36.2%
2025-08-07	308,810	4,452	527,399	58.6%
2025-08-06	202,151	12,590	548,349	36.9%
2025-08-05	256,295	13,237	826,283	31.0%
2025-08-04	411,114	36,303	729,949	56.3%
2025-08-01	350,060	60,108	764,943	45.8%
2025-07-31	829,191	6,023	1,541,015	53.8%
2025-07-30	533,885	14,703	942,788	56.6%
2025-07-29	164,268	55	384,537	42.7%
2025-07-28	150,240	69	571,965	26.3%
2025-07-25	90,782	429	298,801	30.4%
2025-07-24	132,001	11,546	286,155	46.1%
2025-07-23	184,149	63	312,340	59.0%
2025-07-22	134,761	7,553	524,612	25.7%
2025-07-21	113,303	101	243,119	46.6%
2025-07-18	84,117	9	196,317	42.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Edge MSCI USA Momentum Factor UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	IUMD(USD) LSE
ETF Ticker	IUMD.L(GBP) LSE